

# Jennifer R Grandis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2880548/publications.pdf>

Version: 2024-02-01

142  
papers

12,565  
citations

50276

46  
h-index

26613

107  
g-index

145  
all docs

145  
docs citations

145  
times ranked

17784  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Mutational Landscape of Head and Neck Squamous Cell Carcinoma. <i>Science</i> , 2011, 333, 1157-1160.	12.6	2,225
2	Targeting the IL-6/JAK/STAT3 signalling axis in cancer. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 234-248.	27.6	1,789
3	Head and neck squamous cell carcinoma. <i>Nature Reviews Disease Primers</i> , 2020, 6, 92.	30.5	1,649
4	Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers. <i>Cancer Discovery</i> , 2013, 3, 761-769.	9.4	505
5	STAT3 SIGNALING: Anticancer Strategies and Challenges. <i>Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics</i> , 2011, 11, 18-26.	3.4	350
6	Characterization of HPV and host genome interactions in primary head and neck cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 15544-15549.	7.1	317
7	First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy. <i>Cancer Discovery</i> , 2012, 2, 694-705.	9.4	260
8	Exome and genome sequencing of nasopharynx cancer identifies NF- $\kappa$ B pathway activating mutations. <i>Nature Communications</i> , 2017, 8, 14121.	12.8	227
9	HGF and c-Met Participate in Paracrine Tumorigenic Pathways in Head and Neck Squamous Cell Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 3740-3750.	7.0	196
10	EGFR-targeted therapies in the post-genomic era. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 463-473.	5.9	182
11	Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in <i>RAS</i> mutant cancers. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	174
12	Genome-wide association analyses identify new susceptibility loci for oral cavity and pharyngeal cancer. <i>Nature Genetics</i> , 2016, 48, 1544-1550.	21.4	164
13	The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations. <i>Oral Oncology</i> , 2016, 56, 84-92.	1.5	141
14	Targeting Stat3 Abrogates EGFR Inhibitor Resistance in Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 4986-4996.	7.0	135
15	Induction Docetaxel, Cisplatin, and Cetuximab Followed by Concurrent Radiotherapy, Cisplatin, and Cetuximab and Maintenance Cetuximab in Patients With Locally Advanced Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 5294-5300.	1.6	132
16	Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss. <i>Nature Genetics</i> , 2014, 46, 939-943.	21.4	126
17	Dual Blockade of EGFR and c-Met Abrogates Redundant Signaling and Proliferation in Head and Neck Carcinoma Cells. <i>Clinical Cancer Research</i> , 2011, 17, 4425-4438.	7.0	106
18	TGF- $\beta$ and EGFR in head and neck cancer. <i>Journal of Cellular Biochemistry</i> , 1993, 53, 188-191.	2.6	100

#	ARTICLE	IF	CITATIONS
19	HPV-Associated Head and Neck Cancer: Unique Features of Epidemiology and Clinical Management. <i>Annual Review of Medicine</i> , 2016, 67, 91-101.	12.2	97
20	Emerging drugs to treat squamous cell carcinomas of the head and neck. <i>Expert Opinion on Emerging Drugs</i> , 2010, 15, 355-373.	2.4	96
21	Genomic Analysis of Head and Neck Squamous Cell Carcinoma Cell Lines and Human Tumors: A Rational Approach to Preclinical Model Selection. <i>Molecular Cancer Research</i> , 2014, 12, 571-582.	3.4	94
22	c-Src Activation Mediates Erlotinib Resistance in Head and Neck Cancer by Stimulating c-Met. <i>Clinical Cancer Research</i> , 2013, 19, 380-392.	7.0	90
23	Dual Kinase Inhibition of EGFR and HER2 Overcomes Resistance to Cetuximab in a Novel <i>in Vivo</i> Model of Acquired Cetuximab Resistance. <i>Clinical Cancer Research</i> , 2011, 17, 5935-5944.	7.0	87
24	Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 1114-1119.	7.1	86
25	To "Grow" or "Go": TMEM16A Expression as a Switch between Tumor Growth and Metastasis in SCCHN. <i>Clinical Cancer Research</i> , 2014, 20, 4673-4688.	7.0	86
26	APOBEC-induced mutations and their cancer effect size in head and neck squamous cell carcinoma. <i>Oncogene</i> , 2019, 38, 3475-3487.	5.9	81
27	Therapeutic Insights from Genomic Studies of Head and Neck Squamous Cell Carcinomas. <i>Cancer Discovery</i> , 2015, 5, 239-244.	9.4	80
28	Targeting Epidermal Growth Factor Receptor and Src Pathways in Head and Neck Cancer. <i>Seminars in Oncology</i> , 2008, 35, 286-297.	2.2	79
29	HER2 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 526-533.	7.0	77
30	Prevention of Carcinogen-Induced Oral Cancer by Sulforaphane. <i>Cancer Prevention Research</i> , 2016, 9, 547-557.	1.5	77
31	HGF/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment. <i>Clinical Cancer Research</i> , 2016, 22, 4005-4013.	7.0	75
32	Multiple Routes to Oncogenesis Are Promoted by the Human Papillomavirus "Host Protein Network. <i>Cancer Discovery</i> , 2018, 8, 1474-1489.	9.4	67
33	BET Inhibition Overcomes Receptor Tyrosine Kinase-Mediated Cetuximab Resistance in HNSCC. <i>Cancer Research</i> , 2018, 78, 4331-4343.	0.9	66
34	Intratumoral Epidermal Growth Factor Receptor Antisense DNA Therapy in Head and Neck Cancer: First Human Application and Potential Antitumor Mechanisms. <i>Journal of Clinical Oncology</i> , 2009, 27, 1235-1242.	1.6	63
35	JAK Kinase Inhibition Abrogates STAT3 Activation and Head and Neck Squamous Cell Carcinoma Tumor Growth. <i>Neoplasia</i> , 2015, 17, 256-264.	5.3	59
36	Caspase-8 mutations in head and neck cancer confer resistance to death receptor-mediated apoptosis and enhance migration, invasion, and tumor growth. <i>Molecular Oncology</i> , 2014, 8, 1220-1230.	4.6	58

#	ARTICLE	IF	CITATIONS
37	Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 2211-2220.	4.1	56
38	PIK3CA, HRAS and PTEN in human papillomavirus positive oropharyngeal squamous cell carcinoma. <i>BMC Cancer</i> , 2013, 13, 602.	2.6	56
39	Inhibition of EGFR-STAT3 Signaling with Erlotinib Prevents Carcinogenesis in a Chemically-Induced Mouse Model of Oral Squamous Cell Carcinoma. <i>Cancer Prevention Research</i> , 2011, 4, 230-237.	1.5	55
40	The non-coding landscape of head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 51211-51222.	1.8	53
41	Ultrasound Targeted Microbubble Destruction-Mediated Delivery of a Transcription Factor Decoy Inhibits STAT3 Signaling and Tumor Growth. <i>Theranostics</i> , 2015, 5, 1378-1387.	10.0	51
42	Loss-of-Function PTPRD Mutations Lead to Increased STAT3 Activation and Sensitivity to STAT3 Inhibition in Head and Neck Cancer. <i>PLoS ONE</i> , 2015, 10, e0135750.	2.5	51
43	The Fanconi anemia pathway: Repairing the link between DNA damage and squamous cell carcinoma. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2013, 743-744, 78-88.	1.0	50
44	Identifying and Quantifying Heterogeneity in High Content Analysis: Application of Heterogeneity Indices to Drug Discovery. <i>PLoS ONE</i> , 2014, 9, e102678.	2.5	50
45	Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, 1759-1764.	2.0	50
46	New Therapies in Head and Neck Cancer. <i>Trends in Cancer</i> , 2018, 4, 385-396.	7.4	50
47	Erlotinib, Erlotinib+Sulindac versus Placebo: A Randomized, Double-Blind, Placebo-Controlled Window Trial in Operable Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 3289-3298.	7.0	48
48	Proteomic Characterization of Head and Neck Cancer Patient-Derived Xenografts. <i>Molecular Cancer Research</i> , 2016, 14, 278-286.	3.4	48
49	Lack of toxicity of a STAT3 decoy oligonucleotide. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 983-995.	2.3	47
50	The <i>RARS</i> - <i>MAD1L1</i> Fusion Gene Induces Cancer Stem Cell-like Properties and Therapeutic Resistance in Nasopharyngeal Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 659-673.	7.0	47
51	Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for <i>PIK3CA</i> -altered head and neck cancer. <i>Journal of Experimental Medicine</i> , 2019, 216, 419-427.	8.5	46
52	Increased Expression of HER2, HER3, and HER2:HER3 Heterodimers in HPV-Positive HNSCC Using a Novel Proximity-Based Assay: Implications for Targeted Therapies. <i>Clinical Cancer Research</i> , 2015, 21, 4597-4606.	7.0	45
53	Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients. <i>Clinical Cancer Research</i> , 2017, 23, 3072-3083.	7.0	45
54	Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer. <i>JCI Insight</i> , 2017, 2, e90449.	5.0	45

#	ARTICLE	IF	CITATIONS
55	Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma. <i>JAMA Oncology</i> , 2015, 1, 238.	7.1	44
56	An update: emerging drugs to treat squamous cell carcinomas of the head and neck. <i>Expert Opinion on Emerging Drugs</i> , 2018, 23, 283-299.	2.4	44
57	Integration of molecular targeted therapy with radiation in head and neck cancer. , 2014, 142, 88-98.		43
58	Expression of EGFR, VEGF, and NOTCH1 Suggest Differences in Tumor Angiogenesis in HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinoma. <i>Head and Neck Pathology</i> , 2013, 7, 344-355.	2.6	39
59	Emerging drugs for head and neck cancer. <i>Expert Opinion on Emerging Drugs</i> , 2015, 20, 313-329.	2.4	39
60	Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer. <i>Nature Communications</i> , 2021, 12, 2383.	12.8	39
61	The Efficacy of Topical Antibiotic Prophylaxis for Contaminated Head and Neck Surgery. <i>Laryngoscope</i> , 1994, 104, 719-724.	2.0	38
62	A protein network map of head and neck cancer reveals PIK3CA mutant drug sensitivity. <i>Science</i> , 2021, 374, eabf2911.	12.6	37
63	Systemic Administration of a Cyclic Signal Transducer and Activator of Transcription 3 (STAT3) Decoy Oligonucleotide Inhibits Tumor Growth without Inducing Toxicological Effects. <i>Molecular Medicine</i> , 2014, 20, 46-56.	4.4	34
64	MicroRNA-363 targets myosin 1B to reduce cellular migration in head and neck cancer. <i>BMC Cancer</i> , 2015, 15, 861.	2.6	34
65	ATR inhibition sensitizes HPV <sup>-</sup> and HPV <sup>+</sup> head and neck squamous cell carcinoma to cisplatin. <i>Oral Oncology</i> , 2019, 95, 35-42.	1.5	34
66	Head and Neck Cancer: Table 1. <i>Cancer Research</i> , 2004, 64, 8126-8129.	0.9	33
67	Women's Experiences of Promotion and Tenure in Academic Medicine and Potential Implications for Gender Disparities in Career Advancement. <i>JAMA Network Open</i> , 2021, 4, e2125843.	5.9	33
68	Targeting STAT3 in Cancer with Nucleotide Therapeutics. <i>Cancers</i> , 2019, 11, 1681.	3.7	32
69	Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer. <i>Cancer Research</i> , 2018, 78, 2383-2395.	0.9	31
70	STAT3 Cyclic Decoy Demonstrates Robust Antitumor Effects in Non-Small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 1917-1926.	4.1	30
71	PD-1 <sup>+</sup> CXCR5 <sup>+</sup> CD4 <sup>+</sup> Th-CXCL13 cell subset drives B cells into tertiary lymphoid structures of nasopharyngeal carcinoma. , 2021, 9, e002101.		30
72	Nucleic acid-based approaches to STAT inhibition. <i>Jak-stat</i> , 2012, 1, 285-291.	2.2	29

#	ARTICLE	IF	CITATIONS
73	New Strategies in Esophageal Carcinoma: Translational Insights from Signaling Pathways and Immune Checkpoints. <i>Clinical Cancer Research</i> , 2016, 22, 4283-4290.	7.0	29
74	High-Content pSTAT3/1 Imaging Assays to Screen for Selective Inhibitors of STAT3 Pathway Activation in Head and Neck Cancer Cell Lines. <i>Assay and Drug Development Technologies</i> , 2014, 12, 55-79.	1.2	28
75	Paradigm shift in the pathogenesis and treatment of oral cancer and other cancers focused on the oralome and antimicrobial-based therapeutics. <i>Periodontology 2000</i> , 2021, 87, 76-93.	13.4	28
76	Preclinical modeling of EGFR inhibitor resistance in head and neck cancer. <i>Cancer Biology and Therapy</i> , 2012, 13, 935-945.	3.4	27
77	Optimization of pyrazole-containing 1,2,4-triazolo-[3,4-b]thiadiazines, a new class of STAT3 pathway inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 3581-3585.	2.2	27
78	Quantifying Metabolic Heterogeneity in Head and Neck Tumors in Real Time: 2-DG Uptake Is Highest in Hypoxic Tumor Regions. <i>PLoS ONE</i> , 2014, 9, e102452.	2.5	25
79	NSAID therapy for PIK3CA-Altered colorectal, breast, and head and neck cancer. <i>Advances in Biological Regulation</i> , 2020, 75, 100653.	2.3	25
80	HCS Campaign to Identify Selective Inhibitors of IL-6-Induced STAT3 Pathway Activation in Head and Neck Cancer Cell Lines. <i>Assay and Drug Development Technologies</i> , 2015, 13, 356-376.	1.2	24
81	Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients. <i>Clinical Cancer Research</i> , 2019, 25, 5752-5758.	7.0	24
82	Therapeutic Implications of the Genetic Landscape of Head and Neck Cancer. <i>Seminars in Radiation Oncology</i> , 2018, 28, 2-11.	2.2	23
83	Overexpression-mediated activation of MET in the Golgi promotes HER3/ERBB3 phosphorylation. <i>Oncogene</i> , 2019, 38, 1936-1950.	5.9	23
84	STAT3 Oligonucleotide Inhibits Tumor Angiogenesis in Preclinical Models of Squamous Cell Carcinoma. <i>PLoS ONE</i> , 2014, 9, e81819.	2.5	22
85	Targeting the JAK/STAT pathway in solid tumors. <i>Journal of Cancer Metastasis and Treatment</i> , 2020, 6, .	0.8	21
86	Single-agent obatoclox (GX15-070) potently induces apoptosis and pro-survival autophagy in head and neck squamous cell carcinoma cells. <i>Oral Oncology</i> , 2014, 50, 120-127.	1.5	20
87	A watershed year for improvements in treatment?. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 76-78.	27.6	20
88	Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	20
89	Phase I Study of Ficlatazumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer. <i>Cancers</i> , 2020, 12, 1537.	3.7	19
90	Critical analysis of the potential for targeting STAT3 in human malignancy. <i>OncoTargets and Therapy</i> , 2013, 6, 999.	2.0	18

#	ARTICLE	IF	CITATIONS
91	Treatment of Fanconi Anemiaâ€‘Associated Head and Neck Cancer: Opportunities to Improve Outcomes. <i>Clinical Cancer Research</i> , 2021, 27, 5168-5187.	7.0	18
92	Pathway-Specific Genome Editing of PI3K/mTOR Tumor Suppressor Genes Reveals that <i>PTEN</i> Loss Contributes to Cetuximab Resistance in Head and Neck Cancer. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1562-1571.	4.1	17
93	Challenges in EGFRvIII Detection in Head and Neck Squamous Cell Carcinoma. <i>PLoS ONE</i> , 2015, 10, e0117781.	2.5	16
94	Identification of epidermal growth factor receptor (EGFR) genetic variants that modify risk for head and neck squamous cell carcinoma. <i>Cancer Letters</i> , 2015, 357, 549-556.	7.2	16
95	2-Guanidinoquinazolines as new inhibitors of the STAT3 pathway. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 5081-5085.	2.2	15
96	Treatment of head and neck cancer in the elderly. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1903-1921.	1.8	15
97	Oral Cancer Chemopreventionâ€‘The End of EPOC, the Beginning of an Epoch of Molecular Selection. <i>JAMA Oncology</i> , 2016, 2, 178.	7.1	14
98	HER3 targeting potentiates growth suppressive effects of the PI3K inhibitor BYL719 in pre-clinical models of head and neck squamous cell carcinoma. <i>Scientific Reports</i> , 2019, 9, 9130.	3.3	14
99	Investigational multitargeted kinase inhibitors in development for head and neck neoplasms. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 351-363.	4.1	14
100	Alterations and molecular targeting of the GSK-3 regulator, PI3K, in head and neck cancer. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2020, 1867, 118679.	4.1	14
101	CYLD Alterations in the Tumorigenesis and Progression of Human Papillomavirusâ€‘Associated Head and Neck Cancers. <i>Molecular Cancer Research</i> , 2021, 19, 14-24.	3.4	14
102	Synergistic enhancement by interleukin-1 ? of cisplatin-mediated antitumor activity in RIF-1 tumor-bearing C3H/HeJ mice. <i>Cancer Chemotherapy and Pharmacology</i> , 1993, 32, 339-346.	2.3	13
103	Nonpromoter methylation of the CDKN2A gene with active transcription is associated with improved locoregional control in laryngeal squamous cell carcinoma. <i>Cancer Medicine</i> , 2017, 6, 397-407.	2.8	13
104	STAT3 as a Chemoprevention Target in Carcinogen-Induced Head and Neck Squamous Cell Carcinoma. <i>Cancer Prevention Research</i> , 2016, 9, 657-663.	1.5	12
105	Analysis of oncogenic activities of protein kinase D1 in head and neck squamous cell carcinoma. <i>BMC Cancer</i> , 2018, 18, 1107.	2.6	12
106	Biochemical Properties of a Decoy Oligodeoxynucleotide Inhibitor of STAT3 Transcription Factor. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1608.	4.1	11
107	Mentoring Relationships and Gender Inequities in Academic Medicine: Findings From a Multi-Institutional Qualitative Study. <i>Academic Medicine</i> , 2022, 97, 136-142.	1.6	11
108	STAT3 decoy oligonucleotide-carrying microbubbles with pulsed ultrasound for enhanced therapeutic effect in head and neck tumors. <i>PLoS ONE</i> , 2020, 15, e0242264.	2.5	11

#	ARTICLE	IF	CITATIONS
109	Mechanism of action of selective inhibitors of IL-6 induced STAT3 pathway in head and neck cancer cell lines. <i>Journal of Chemical Biology</i> , 2017, 10, 129-141.	2.2	10
110	Targeting STAT3 with Proteolysis Targeting Chimeras and Next-Generation Antisense Oligonucleotides. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 219-228.	4.1	10
111	Caspase-8 mutations associated with head and neck cancer differentially retain functional properties related to TRAIL-induced apoptosis and cytokine induction. <i>Cell Death and Disease</i> , 2021, 12, 775.	6.3	10
112	Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancer. <i>JCI Insight</i> , 2021, 6, .	5.0	10
113	Spot the difference. <i>Nature</i> , 2017, 541, 162-163.	27.8	9
114	Phase 1 study of EGFR antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives. <i>Cancer</i> , 2018, 124, 3881-3889.	4.1	8
115	IGF2 Mediates Resistance to Isoform-Selective-Inhibitors of the PI3K in HPV Positive Head and Neck Cancer. <i>Cancers</i> , 2021, 13, 2250.	3.7	8
116	MAPK1E322K mutation increases head and neck squamous cell carcinoma sensitivity to erlotinib through enhanced secretion of amphiregulin. <i>Oncotarget</i> , 2016, 7, 23300-23311.	1.8	8
117	Toxicity, pharmacokinetics and metabolism of a novel inhibitor of IL-6-induced STAT3 activation. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 1225-1235.	2.3	7
118	PD-L1 is upregulated via BRD2 in head and neck squamous cell carcinoma models of acquired cetuximab resistance. <i>Head and Neck</i> , 2021, 43, 3364-3373.	2.0	7
119	Established and Emerging Concepts in Epidermal Growth Factor Receptor Biology. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, S22-S24.	0.8	6
120	Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance. <i>PLoS ONE</i> , 2020, 15, e0227261.	2.5	6
121	Gene targets of sulforaphane in head and neck squamous cell carcinoma. <i>Molecular Medicine Reports</i> , 2019, 20, 5335-5344.	2.4	6
122	Prognostic biomarkers in patients with human immunodeficiency virus positive disease with head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2017, 39, 2433-2443.	2.0	5
123	Erlotinib, dasatinib, erlotinib-dasatinib versus placebo: A randomized, double-blind window study in operable head and neck squamous cell carcinoma (HNSCC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 6033-6033.	1.6	5
124	Phase II trial of radiotherapy (RT) with concurrent cisplatin (C) plus panitumumab (pmAb) for patients (pts) with high-risk, resected head and neck cancer (HNC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 6090-6090.	1.6	5
125	Genomic and Transcriptomic Alterations Associated with STAT3 Activation in Head and Neck Cancer. <i>PLoS ONE</i> , 2016, 11, e0166185.	2.5	4
126	NSAIDs Overcome PIK3CA Mutation-Mediated Resistance to EGFR Inhibition in Head and Neck Cancer Preclinical Models. <i>Cancers</i> , 2022, 14, 506.	3.7	4



#	ARTICLE	IF	CITATIONS
127	Head and Neck Cancer among American Indian and Alaska Native Populations in California, 2009â€“2018. <i>Cancers</i> , 2021, 13, 5195.	3.7	3
128	Jak/STAT Signaling in Head and Neck Cancer. <i>Current Cancer Research</i> , 2018, , 155-184.	0.2	3
129	Abstract 4101: Targeting the EGFR/STAT3 axis in NSCLC with resistance to EGFR tyrosine kinase inhibitors using an oligonucleotide-based decoy. , 2017, , .		2
130	Networking practices and gender inequities in academic medicine: Women's and men's perspectives. <i>EClinicalMedicine</i> , 2022, 45, 101338.	7.1	2
131	HER2 and HER3 in HPV+ and HPVâ€™ HNSCCâ€™Response. <i>Clinical Cancer Research</i> , 2016, 22, 1826-1826.	7.0	1
132	A Young Man With Chronic Discharge From the Skin of the Lateral Neck. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2016, 142, 99.	2.2	1
133	The Mutational Landscape of Head and Neck Squamous Cell Carcinoma: Opportunities for Detection and Monitoring Via Analysis of Circulating Tumor DNA. , 2021, , 107-122.		1
134	Gender Equity in Science and Medicine: Breaking the Impasse. <i>Cancer Discovery</i> , 2022, 12, 1191-1194.	9.4	1
135	Targeting Members of the Epidermal Growth Factor Receptor Family to Improve Response to Chemotherapy. , 2019, , 1-23.		0
136	Expression of tumor biomarkers in HIV-infected patients with head and neck cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 6086-6086.	1.6	0
137	Prevalence and outcome of mutations (mut) in the Fanconi anemia (FA) DNA repair pathway among head and neck cancer (H&N Ca) patients (pts).. <i>Journal of Clinical Oncology</i> , 2014, 32, 6036-6036.	1.6	0
138	A sensible approach to targeting STAT3-mediated transcription. <i>Annals of Translational Medicine</i> , 2016, 4, S57-S57.	1.7	0
139	Title is missing!. , 2020, 15, e0227261.		0
140	Title is missing!. , 2020, 15, e0227261.		0
141	Title is missing!. , 2020, 15, e0227261.		0
142	Title is missing!. , 2020, 15, e0227261.		0